Shikiar Asset Management Inc. Increases Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Shikiar Asset Management Inc. increased its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 17.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 127,040 shares of the company's stock after purchasing an additional 18,921 shares during the quarter. Novo Nordisk A/S makes up 4.1% of Shikiar Asset Management Inc.'s portfolio, making the stock its 9th biggest position. Shikiar Asset Management Inc.'s holdings in Novo Nordisk A/S were worth $13,142,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Roundview Capital LLC boosted its holdings in Novo Nordisk A/S by 0.6% during the first quarter. Roundview Capital LLC now owns 18,803 shares of the company's stock worth $2,088,000 after buying an additional 106 shares during the last quarter. BlackRock Inc. boosted its holdings in Novo Nordisk A/S by 45.4% during the first quarter. BlackRock Inc. now owns 5,035,879 shares of the company's stock worth $559,235,000 after buying an additional 1,571,747 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Novo Nordisk A/S by 0.9% during the first quarter. Dimensional Fund Advisors LP now owns 739,585 shares of the company's stock worth $82,131,000 after buying an additional 6,903 shares during the last quarter. Blair William & Co. IL boosted its holdings in Novo Nordisk A/S by 12.7% during the first quarter. Blair William & Co. IL now owns 19,466 shares of the company's stock worth $2,136,000 after buying an additional 2,194 shares during the last quarter. Finally, Sei Investments Co. boosted its holdings in Novo Nordisk A/S by 17.5% during the first quarter. Sei Investments Co. now owns 107,175 shares of the company's stock worth $11,913,000 after buying an additional 15,996 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on NVO. BMO Capital Markets began coverage on Novo Nordisk A/S in a report on Friday, April 12th. They set an "outperform" rating and a $163.00 target price on the stock. Morgan Stanley assumed coverage on Novo Nordisk A/S in a report on Tuesday, January 23rd. They set an "overweight" rating and a $120.00 price objective on the stock. UBS Group assumed coverage on Novo Nordisk A/S in a report on Tuesday, January 16th. They set a "neutral" rating on the stock. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a report on Thursday. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $133.60.

Novo Nordisk A/S Stock Down 0.0 %

Novo Nordisk A/S stock traded down $0.04 during midday trading on Friday, reaching $122.71. The stock had a trading volume of 5,183,469 shares, compared to its average volume of 3,262,533. The firm's fifty day simple moving average is $126.39 and its 200-day simple moving average is $111.03. Novo Nordisk A/S has a 1-year low of $75.56 and a 1-year high of $138.28. The stock has a market capitalization of $550.66 billion, a P/E ratio of 45.36, a price-to-earnings-growth ratio of 2.05 and a beta of 0.41. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.64 and a current ratio of 0.82.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its earnings results on Wednesday, January 31st. The company reported $0.71 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.66 by $0.05. Novo Nordisk A/S had a return on equity of 90.36% and a net margin of 36.03%. The business had revenue of $9.51 billion for the quarter, compared to analyst estimates of $9.14 billion. As a group, analysts expect that Novo Nordisk A/S will post 3.32 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently declared a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Shareholders of record on Monday, March 25th were given a dividend of $0.664 per share. This is a positive change from Novo Nordisk A/S's previous Semi-Annual dividend of $0.22. The ex-dividend date was Friday, March 22nd. This represents a dividend yield of 0.9%. Novo Nordisk A/S's payout ratio is 49.17%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.